本帖最后由 老马 于 2012-1-13 21:20 编辑 * R8 e2 S7 ^2 I" |: f( U5 ~4 h, _! n
7 |9 o1 M! B& {$ ]爱必妥和阿瓦斯丁的比较, @# S$ Q' G( u4 ^9 g
. _1 ~4 A, \, N1 ~8 p
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 k7 r* T& G4 |% I9 D
8 H5 _+ }: Z/ Z: `+ Z
% f( _5 M/ O5 l! ]) n) r' T7 s0 P
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
- H2 b$ s* {7 [9 g6 L- Y* V7 }, l==================================================
4 D; G' e2 x! I: u: N3 BOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, u9 N7 P1 S. W5 ]8 z8 ZPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 C7 Q# u6 q* j+ @9 }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ O6 U! }% L& m+ q4 K* E, S
|